Find Clinical Trials

InclusionCriteria: * Age \> 18 years * All patients will be obese asthmatics. Patients will have a body mass index \>30 and insulin resistance\>5. * Asthmatics who have stable disease without changes to their asthma related medications for 3 months prior to enrollment Exclusion Criteria: * Asthma related hospitalization within 90 days of enrollment * Asthma exacerbation requiring \>3 days of oral corticosteroids within 28 days of enrollment * Comorbid lung diseases other than asthma * Pregnancy or planned pregnancy * Inability to understand study procedures and/or provide informed consent * Other significant medical conditions based on discretion of PI

Inclusion Criteria: * Sign a written informed consent to participate in the trial and receive treatment; * Major depressive disorder diagnosis; * Hamilton depression scale (HAMD - 24) 24 total score 20 points or more; * First episode or recurrence of depression patients, not taking psychiatric drugs; * The han nationality, right-handed; * Junior high school or above; Exclusion Criteria: * Other organic mental disorders and mental retardation and other severe mental disorders; * Infection, trauma, and autoimmune diseases or other possible interference test evaluation of disease; * Alcohol and drug dependence or is being treated for a hormone drugs patients; * Craniocerebral injury; * Seizure or a family history of epilepsy; * Pregnancy and lactation women; * All landowners had a metal and MRI contraindications or MRI examination revealed abnormal brain structure.

Inclusion Criteria: * Documented diagnosis of OSA * Currently on CPAP or BiPAP for at least 3 months * with documented adherence (defined as wearing CPAP/BiPAP for \>6h/night on at least 75% of nights), and adequate control of sleep apnea, as indicated by an AHI of 10 or less when on CPAP * Excessive residual daytime sleepiness (Epworth score \> 10) * If taking alertness promoting medication, the investigators will require that they are on a stable dose for at least one month prior to entering the study and that they refrain from dose changes while participating in the study * If already prescribed BLT, subjects must not have used it for at least one month prior to participating Exclusion Criteria: * Shift work * Travel across time zones in the past month * Narcolepsy * Regular hypnotics use * Decompensated congestive heart failure (CHF) * Primary central sleep apnea, needing O2 therapy via nasal cannula * Poorly controlled diabetes (HgA1c\>8%) * Active substance use disorder * Dementia * Untreated bipolar disorder * the investigators will consider individuals with a diagnosis of bipolar disorder who are currently in treatment and stable * Macular degeneration, recent lasik surgery (within 3 months) * Legally blind * Taking medication that will cause photosensitivity to blue-green light spectrum wavelength * Already using bright light therapy

Inclusion Criteria: 1. The patient voluntarily joined the study and signed an informed consent form; 2. ≥18 and ≤ 75 years old, both male and female; 3. Clinically diagnosed or pathologically confirmed hepatocellular carcinoma, at least one measurable focus without local treatment (according to mRECIST requirements, the measurable focus spiral CT scan length ≥ 10 mm or enlargement Short diameter of lymph node ≥15 mm); 4. Child-Pugh score ≤ 13 points; 5. BCLC-C stage accompanied by tumor thrombosis-associated portal hypertension; 6. Newly diagnosed patients who have not received targeted therapy or immunotherapy in the past; 7. ECOG score: 0～1; 8. Expected survival period ≥ 12 weeks; 9. The functions of vital organs meet the following requirements (no blood components, cell growth factors and other corrective treatment drugs are allowed within 14 days before the first administration): 10. The absolute count of neutrophils≥1.5×109/L; Platelet ≥50×109/L; Hemoglobin ≥60 g/L; Serum albumin ≥28 g/L; Thyroid-stimulating hormone (TSH)≤1×ULN (if abnormal, the levels of FT3 and FT4 should be examined at the same time, if the levels of FT3 and FT4 are normal, they can be included in the group); Bilirubin≤2×ULN (within 7 days before the first administration); ALT and AST ≤5×ULN (within 7 days before the first dose); Serum creatinine≤1.5×ULN; 11. Non-surgical sterilization or female patients of childbearing age need to use a medically approved contraceptive method (such as an intrauterine device, contraceptive, or condom) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo surgical sterilization must be negative in serum or urine HCG within 72 hours before enrollment in the study; and must be non-lactating; for male patients whose partners are women of childbearing age, at the last time use effective methods for contraception within 3 months. Exclusion Criteria: 1. The patient has any active autoimmune disease or a history of autoimmune disease; 2. The patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before enrollment; 3. The number of system treatment lines ≥ 2 lines; 4. Severe allergic reaction to other monoclonal antibodies; 5. Those with a known history of central nervous system metastasis or hepatic encephalopathy; 6. Patients who have received liver transplantation in the past; 7. Tumor thrombus beyond the portal vein range, such as hepatic vein, inferior vena cava, right atrium, splenic vein, superior mesenteric vein cancer thrombus, etc.; 8. Suffer from high blood pressure and cannot be well controlled by antihypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); 9. Uncontrolled cardiac clinical symptoms or diseases, such as: NYHA level 2 or higher heart failure, unstable angina pectoris, myocardial infarction occurred within 1 year, clinically significant supraventricular or ventricular arrhythmia requires treatment or intervention , QTc\>450ms (male); QTc\>470ms (female); 10. Abnormal coagulation function (INR\>2.0, PT\>16s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy, and allow the preventive use of low-dose aspirin and low molecular heparin; 11. Child-Pugh score \>13 points; 12. Arterial/venous thrombosis events that occurred within 6 months before randomization, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; 13. Known genetic or acquired bleeding and thrombotic tendency (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, etc.); Urine routine test showed urine protein ≥ ++ and confirmed 24-hour urine protein content\> 1.0 g; 14. Patients who have previously received radiotherapy, chemotherapy, hormone therapy, and surgery, after the completion of the treatment (last medication) and less than 4 weeks before the study medication; molecular targeted therapy (including other oral targeted drugs used in clinical trials) is less than the first study medication \<5 drug half-lives, or patients whose adverse events (except alopecia) caused by previous treatment have not recovered to ≤ CTCAE level 1; 15. The patient has active infection, fever of unknown origin within 7 days before medication ≥38.5℃, or baseline white blood cell count \>15×109/L; Patients with congenital or acquired immune deficiencies (such as HIV-infected persons); 16. Moderate to severe pulmonary hypertension, pulmonary artery pressure was assessed by ultrasound \>40mmHg； 17. The patient suffered from other malignant tumors in the past 3 years or at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ); 18. Central nervous system metastasis； 19. The patient has previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1, or has previously received apatinib therapy; 20. Live vaccine may be vaccinated less than 4 weeks before study medication or may be administered during the study period; 21. According to the judgment of the investigator, the patient has other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, and serious laboratory tests 22. Abnormalities, accompanied by family or social factors, will affect the safety of patients.

Inclusion Criteria: * Female and male breast cancer patients aged ≥18 years. * Patients with primary early breast cancer (irrespective of subtypes) or - as an exception - patients with isolated loco-regional relapses that can be treated with a curative intention * Study entry is possible for patients with primary eBC at three timepoints: * Option A: patients planned to receive neoadjuvant chemotherapy are enrolled before starting the neoadjuvant treatment * Option B: patients with clinical non-complete response can be enrolled after the last cycle of neoadjuvant chemotherapy before surgery Note: Option A/B are strongly preferred entry time-points * Option C: eBC patients after surgery and planned or conducting standard-of-care (SoC) post-neoadjuvant chemotherapy can be enrolled after surgery until the last cycle of standard post-neoadjuvant chemotherapy, if they fulfill the following criteria * HER2+ BC or TNBC: non-pCR * HR+/HER2- BC: non-pCR and CPS-EG score ≥ 3 or non-pCR, ypN+ and CPS-EG-score ≥ 2 Note: Option C is not the preferred entry time-point Note: in case of loco-regional relapse, neoadjuvant treatment is not mandatory * Patients must be willing to donate a recent tumour sample to the registry Note: fresh tumour tissue is preferred * Patients, who agreed to and were able to sign the informed consent form (ICF). Exclusion Criteria: * Patients who did not sign or withdrew the informed consent form (ICF). * Inability to retrieve tissue for molecular profiling Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Inclusion Criteria: * Women, 18 years of age or older * Breast cancer patients with hormone receptor positive breast cancer , stage 0-III * Premenopausal or perimenopausal women who have either been pregnant or had at least one menstrual period in the last 24 months or have/had an IUD in place * Patients currently on or are being initiated on ovarian suppression * Patients are asymptomatic for vaginal symptoms of estrogen deprivation (i.e. vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\]) and score a 3 or less on the VAS and VuAS Exclusion Criteria: * Postmenopausal women who have been without a period for ≥ 2 years * Patients who score a 4 or above on the VAS and VuAS * Patients already using VVA treatment (e.g. intravaginal estrogen, other non-hormonal moisturizer or suppository), unless discontinued with washout of 4 weeks

Inclusion Criteria: * Individuals with depressive episode characterized according to the DSM-5 criteria regardless of the associated characteristics and comorbidities. * Adult and child * Affiliated to a social security Exclusion Criteria: * don't understand or read french * Medical condition incompatible with administration of questionnaire * impossibility to give informed decision (subject in an emergency condition, etc.)

Inclusion Criteria: * Patients with type 2 diabetes who had been followed up and treated at the Endocrinology and Metabolic Diseases Polyclinic * Aged between 18-65 years * Patients who know their diagnosis and can verbally express it * Have been diagnosed with type 2 diabetes for at least six months * Who are literate * Who have internet access at home, who have one of the tools such as a computer, tablet or smartphone and can use these tools * Consented to participate in the study * Had no other psychiatric or mental barriers to answering the questions, language or cognitive difficulties, and barriers to verbal or written communication Exclusion Criteria: * Diagnosed with myocardial infarction, stroke or diabetic foot in the last six months * Diagnosed with type 1 diabetes or gestational diabetes * Diagnosed with terminal illness * Using steroid therapy * Had pregnant * Having dementia and cognitive deficits * Having retinopathy or advanced neuropathy * Patients whose information is not allowed to be accessed

Inclusion Criteria: * Patients who have given their written consent to participate in this study * Patients who are 20 years of age or older at the time of consent (regardless of gender) * Patients with type 2 diabetes mellitus * Patients with chronic kidney disease who meet both of the following criteria; i) eGFR greater than 25 mL/min/1.73 m2 and less than 90 mL/min/1.73 m2, ii) UACR greater than 30 mg/g.cr. and less than 3500 mg/g.cr. * Patients who have not changed their medications for type 2 diabetes and chronic kidney disease in the past 4 weeks prior to obtaining consent Exclusion Criteria: * Patients who are currently taking or have taken MRAs containing finerenone in the past 4 weeks prior to obtaining consent. * Patients with a history of hypersensitivity to finerenone * Patients with HbA1c greater than 10%. * Patients with a serum potassium level of 4.9 mEq/L or higher * Patients with NYHA class II-IV HFrEF (LVEF \<35%) * Patients with poorly controlled hypertension (e.g., systolic BP \>170 mmHg, diastolic BP \>110 mmHg, or hypertensive emergencies) * Patients with a history of ischemic stroke, acute coronary syndrome, cardiovascular surgery or percutaneous intervention, or hospitalization for worsening heart or renal failure in the past 8 weeks prior to obtaining consent * Patients with a preplanned surgical or percutaneous intervention for coronary artery reconstruction or other cardiovascular disease during the individual observation period. * Patients with a preplanned treatment such as electrical cardioversion, cardiac resynchronization therapy or pacemaker implantation during the individual observation period. * Patients with preplanned dialysis or kidney transplantation during the individual observation period. * Patients with severe hepatic dysfunction (Child-Pugh Class C) * Patients receiving itraconazole, ritonavir-containing products, atazanavir, darunavir, fosamprenavir, cobicistat-containing products, or clarithromycin, or ensitrelvir * Patients with Addison's disease * Patients with active infectious diseases * Pregnant, possibly pregnant, or lactating patients * Other patients deemed inappropriate for this study by the principal investigator or subinvestigators (e.g., patients with renal artery stenosis, one kidney, or active malignancy).

Key Inclusion criteria: * Adult female or male \>= 18 years of age at the time of informed consent * Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive with ER \>10% (regardless of progesterone receptor (PgR) expression) breast cancer by local laboratory testing (based on the most recently analyzed tissue sample) * HER2 negative breast cancer defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (e.g. fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), or silver in situ hybridization (SISH)) test is required by local laboratory testing (based on the most recently analyzed tissue sample) * Participant has advanced (loco regionally recurrent not amenable to curative therapy (e.g. surgery and/or radiotherapy) or metastatic) breast cancer Participants may be: 1. relapsed with documented evidence of relapse on or within 12 months from completion of (neo)adjuvant endocrine therapy (+/- CDK4/6 inhibitor) with no treatment for advanced disease OR 2. relapsed with documented evidence of relapse more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression after one line of endocrine therapy (except fulvestrant) (+/- CDK4/6 inhibitor) for advanced disease OR 3. advanced breast cancer at diagnosis that progressed with documented evidence of progression after one line of endocrine therapy (except fulvestrant) (+/- CDK4/6 inhibitor) Note: Participant who relapsed with documented evidence of relapse on/or within 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor) for advanced disease will NOT be included in the study. At least one target lesion (i.e., a measurable lesion as per RECIST 1.1) in the baseline stand-alone CT or MRI, showing \[68Ga\]Ga-NeoB uptake on PET/CT or PET/MRI scoring 2 or higher, based on the Visual Scoring Scale. * Adequate bone marrow and organ function as defined by the laboratory values. * Standard 12-lead ECG values defined as the mean of the triplicate ECGs and assessed locally: * QT interval corrected by Fridericia's formula (QTcF) interval at screening \< 450 msec * Mean resting heart rate 50-90 bpm (determined from the ECG) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key Exclusion criteria: * More than one line of prior treatment in the advanced/metastatic setting. Participant shouldn't have received prior fulvestrant treatment. * Documented evidence of prior ribociclib dose reduction due to safety reasons either in adjuvant setting or for advanced disease. * Relapse or disease progression within 6 months of receiving a CDK4/6 inhibitor therapy either in adjuvant setting or for advanced disease. Symptomatic visceral disease or any disease burden that makes the participant ineligible for ribociclib plus endocrine treatment per the Investigator's best judgment. * Presence of central nervous system (CNS) involvement unless meeting BOTH of the following criteria: 1) At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment. 2) Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases. * Currently receiving warfarin or other Coumadin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin, or fondaparinux is allowed. * Diagnosis of inflammatory breast cancer at screening * Child Pugh score B or C * History or current diagnosis of impaired cardiac function, clinically significant cardiac disease or ECG abnormalities indicating significant risk of safety for participants. * Known or expected hypersensitivity to any of the study drugs or any of their excipients. * Prior administration of a radiopharmaceutical unless 10 or more half-lives have elapsed before injection of \[68Ga\]Ga-NeoB or \[177Lu\]Lu-NeoB * Participant has received extended-field RT=\< 4 weeks or limited field RT=\< 2 weeks prior to start of treatment and has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia or other toxicities not considered a safety risk for the participant at Investigator's discretion) and/or prior external beam radiation therapy (EBRT) to more than 25% of the bone marrow. * Participant is currently receiving or has received systemic corticosteroids =\< 2 weeks prior to starting study treatment, or who have not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular) * Participant has a history of or ongoing acute pancreatitis within 1 year of screening. * Participant is currently receiving any of the following substances and cannot be discontinued 7 days prior to starting study treatment: * Concomitant medications, herbal supplements, and/or fruits (e.g., grapefruit, pummelos, star fruit, Seville oranges) and their juices that are strong inducers or inhibitors of cytochrome P450 (CYP) 3A4 * Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5 * Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointes (TdP) that cannot be discontinued or replaced by safe alternative medication (e.g., within 5 half-lives or 7 days prior to starting study treatment) * Participant is currently receiving NEP inhibitors (e.g.Entresto®, racecadotril) and images for dosimetry assessments cannot be acquired for this participant. Other protocol-defined inclusion/exclusion criteria may apply.

Inclusion Criteria: * Age range from 18 to 80 years; * Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes; * A relative scotoma defined as a Humphrey Field Analyser (HFA) threshold perimetry loss (mean deviation of -6dB) within the central 24 degree of the visual field for at least one eye; * Best-corrected distance visual acuity of 6/12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved). * Stable vision and visual field loss for at least 3 months; * With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA) (to confirm participant's intact cognitive function). Exclusion Criteria: * Ocular diseases other than glaucoma (e.g. age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participant can hear the instructions clearly during assessments and training); * Severe medical problems (e.g. stroke, Parkinson's disease) or self-reported neurological (e.g. brain surgery, brain tumor, peripheral neuropathy), or cognitive disorders (e.g. diagnosed dementia or cognitive impairment); * Self-reported vestibular or cerebellar dysfunction, history of vertigo; * Using any medications for any neurological conditions or psychiatric drugs (e.g. sedative, hypnotic) that might interfere motor control; * Contraindications for non-invasive brain stimulation.

Inclusion Criteria: Individual with type 2 diabetes: * Self-identification as African American; * 40 years or older * Type 2 diabetes diagnosis for at least six months; * A1c \> 7.0% at time of enrollment; * Being able to speak and read English; * Being able to walk; * Having an adult family member/close friend willing to co-participate in the study. Family members: * Adults (18 years or older, with or without T2D); * Residing in the same household as the T2D participants; * Being a spouse, adult child or sibling; or close friend * Being able to walk; * Being able to speak and read English. Exclusion Criteria: Individual with T2D and family members: * Being pregnant or have an advanced or terminal condition; * Being cognitively impaired or unable to provide informed consent; * Lack conclusive evidence of T2D for patients with T2D.

Inclusion Criteria: 1. Between 18 and 75 years of age with no gender-based restriction. 2. Fulfilling the diagnostic criteria of DSM-5 for major depressive disorder. 3. A Hamilton Rating Scale for Depression (HDRS-17) score ≥ 17 4. Ability to read and understand Mandarin Chinese, at least nine years of education, and willingness to adhere to the study protocol. 5. The absence of acupuncture treatment within at least 1 year. 6. Willingness to participate in the trial and provide written informed consent for the clinical trial. Exclusion Criteria: 1. Lifetime or current neuropsychiatric conditions, such as bipolar disorder, schizophrenia, substance dependence or abuse, dementia, brain injury, epilepsy and so forth. 2. High suicide risk or presenting with suicidal ideation (a score of more than 2 points on the Suicide question of the HDRS-17) at the time of entry. 3. Medicated with antidepressant at the start of the trial or history of treatment failure to escitalopram. 4. Pregnancy or breastfeeding. 5. Subjects who have acute inflammation at the planned acupuncture site on the body or any other contraindication to acupuncture. 6. Candidates afraid of needles in general and reluctant to receive acupuncture in particular 7. Known or suspected clinically unstable systemic medical disorder (including cancer, organ failure, or severe diseases of the cardiovascular, severe hepatic or renal insufficiency). 8. Previous participation in other acupuncture trials.

Inclusion Criteria: * Adults age 18-65 years inclusive * Current diagnosis of MDD identified by the MINI (Mini Neuropsychiatric Interview) * Current HAM-D17 score of \>= 16 * Adequate adherence to any FDA approved SSRI or SNRI for at least 8 weeks * Right-handed * Residing at \> 4000 ft for at least 12 weeks Exclusion Criteria: * Any non-MDD and non-anxiety psychiatric diagnosis, as identified by the MINI * History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease * Current colitis or diverticulitis * History of or current pulmonary disease (except well controlled asthma) * Current smoking * History of cardiac disease or QTc \> 500ms * History of fibromyalgia or any rheumatological condition * History of or current seizure disorder * Current serious suicide risk identified by the Columbia Severity Suicide Rating Scale * Current treatment with an antipsychotic, mood stabilizer, or non-SSRI/SNRI antidepressant except for bupropion at FDA-approved doses or trazodone up to 200mg, or use of any supplements apart from standard multivitamins * Positive pregnancy test, pregnancy, failure to use adequate birth control method * Previous diagnosis of serotonin syndrome or evidence of serotonin syndrome * Pre-existing eosinophilia (absolute eosinophil count \> 500/uL) * Contraindications to MRI: ferromagnetic implants, implanted devices, claustrophobia

Inclusion Criteria: For pharmacies : * In the province of Quebec, Canada * At least one pharmacist agrees to take charge of the project in their pharmacy * At least one women has initiated adjuvant endocrine therapy (AET) in the last 6 months in the pharmacy For pharmacists : * Practicing in a pharmacy in the province of Quebec * Provide consent For women : * 18 years old or older * Were diagnosed with a first non-metastatic, hormone-sensitive breast cancer * Received and AET prescription for the first time in the last 6 months * Are fluent in French * Have internet access * Provide consent Exclusion Criteria: For women : • Live in a residential facility where AET is not self-managed

Inclusion Criteria: 1. Pathology-confirmed breast cancer patients who meet at least one of the criteria below: * Triple-negative breast cancer * Age ≤ 50 years * Male breast cancer * With personal or family history of malignancy: breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, other malignancies * HER-2 negative recurrent or metastatic breast cancer * HER-2 negative high-risk breast cancer: A: Neoadjuvant phase: non-pathological complete response for triple-negative breast cancer; non-pathological complete response AND CPS+EG score ≥ 3 for hormone receptor positive breast cancer B: Adjuvant phase: ≥ pT2 or ≥ pN1 for triple-negative breast cancer; ≥ 4 lymph node metastasis for hormone receptor positive breast cancer 2. Having been or intended to be tested for germline and (or) somatic homologous recombination repair gene mutations 3. Consent to providing medical charts and homologous recombination repair gene testing results, and being cooperative for long-term follow-up Exclusion Criteria: 1. Homologous recombination repair gene testing results unavailable 2. Other factors deemed by the investigators that may sabotage the study

DIP - Inclusion Criteria: * Immediately postpartum individuals during their delivery hospital admission * ≥ 18 years old with the ability to give informed consent. * Diagnosed with GDM during pregnancy by: * Elevated one-hour 50-gram glucose challenge test any time during pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis OR * Two elevated values on a 3-hour 100-gram glucose tolerance test any time in pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis * English or Spanish speaking * Receiving prenatal and postpartum care at OSU DIP- Exclusion Criteria: * Individuals who cannot tolerate a 2-hour oral glucose tolerance test (OGTT) (i.e. history of gastric bypass) * Not English or Spanish speaking PP CARE Inclusion criteria: Enrolled DIP participants who are English speaking will be eligible for PP CARE follow up if they are between 12 and 24 months postpartum. PP CARE Exclusion criteria: Spanish speaking DIP participants will be excluded because the study team does not include anyone who is Spanish speaking.

Inclusion Criteria: * Self-identify as Latina * Speak Spanish * Be at least 16 years old * Be pregnant or have a child \<9 months * Have access to a device they can use for MB-VG sessions. * Elevated depressive symptoms either scores of 5-14 on the Edinburgh Postnatal Depression Scale (EPDS) and/or scores 3.5 or greater prenatally or 4.5 or greater prenatally on the Postpartum Depression Predictors Inventory. Exclusion Criteria: * Individuals who score \>14 on the EPDS are exhibiting moderately severe to severe depressive symptoms and will be excluded given our prevention focus. * Individuals not at risk for PPD-i.e., EPDS scores \<5 and under the PDPI-R cutoff-will also be excluded.

Inclusion Criteria: * BMI ≥ 28 kg/m2, meeting the indications for surgical weight loss surgery (gastrectomy) * Normal glucose tolerance group: HbA1c ≤ 5.6%; ≥ 6 cases aged 24 years or above * IGT patients: 5.7% ≤ HbA1c ≤ 6.4%; ≥ 12 cases aged 24 years or above * T2DM patients: Subjects with HbA1c ≥ 6.4% or HbA1c well controlled by medication can be diagnosed as T2DM based on self-reported or fasting/postprandial blood glucose diagnosis; ≥ 12 cases aged 24 years and above. * Between the ages of 16 and 65 (inclusive), with no less than one-third of either gender * The subjects understand the content of the informed consent form and voluntarily sign it, which allows them to maintain good communication with the researchers and comply with the requirements of the clinical trial Exclusion Criteria: * Type I diabetes patients (autoimmune diabetes patients with T1DM antibody) * Suffering from special types of diabetes, including cortisolism, growth hormone tumor, glucagon tumor and diabetes caused by some genetic factors * Significant weight loss occurred before enrollment (\>3% weight loss in the first 3 months) * Participated in other research projects as a subject within 6 months prior to screening * Donate or lose ≥ 400 mL of blood within 8 weeks prior to screening * Regular use (cumulative use for 3 months in the past 12 months) or treatment with corticosteroids, contraceptives, thiazide diuretics, and quinolone antibiotics in the past two months * Regular use (cumulative use for 3 months in the past 12 months) or treatment with anti obesity drugs in the past two months * The following hypoglycemic drugs have been used routinely (for 3 months accumulatively in the past 12 months) or in the past two months: sulfonylureas (glibenclamide, glipizide, gliclazide, gliquidone, glimepiride, etc.), non sulfonylureas (repaglinide, nateglinide, migglinide, etc.), GLP-1 receptor agonists (exenatide, lilalutide, etc.) DPP-4 inhibitors (sigliptin, alogliptin, vildagliptin, shagliptin, linagliptin, etc.) or glucokinase agonists (doegliptin, etc.) * Contraindications to magnetic resonance imaging * The risk of complications significantly increases during the perioperative or postoperative period * Those with a history of other weight loss surgeries * Individuals with a history of cardiovascular surgery and severe cardiovascular and pulmonary diseases: including stroke, severe coronary heart disease, arrhythmia, unstable angina, myocardial infarction within 6 months, peripheral vascular disease, heart failure, and uncontrolled hypertension * Clinically significant history of ECG abnormalities or family history of long QT syndrome (grandparents, parents, brothers and sisters) * People with a history of kidney disease: have a history or evidence of renal insufficiency, manifested as clinically significant creatinine abnormalities or urinary composition abnormalities (such as tubular abnormalities), or eGFR\<60 ml/min/1.73m2 * Patients with a history of gastrointestinal surgery (excluding appendectomy and cholecystectomy), inflammatory bowel disease, esophageal disease, including severe refractory esophagitis, Barrett's disease, esophageal motility disorders, or other gastric motility impairments, or those with esophageal hiatal hernia\>3cm in size, chronic or acute bleeding, including peptic ulcer disease, portal hypertension (gastric or esophageal varices), chronic pancreatitis or cirrhosis * Individuals with a history of eating disorders or mental illness * Individuals with a history of infectious diseases are excluded if they have any of the following: human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or those who have tested positive for syphilis * Smokers, those who smoke more than 10 cigarettes or equivalent amounts of tobacco per day and cannot stop smoking during the trial period * There is a history of drug or alcohol abuse within the 12 months prior to the trial, or evidence of such abuse is found during laboratory examinations during the screening period evaluation * Women who are pregnant, breastfeeding, or planning to conceive and are unwilling to use contraception during the trial period * Malignant tumor patients * The researcher believes that it is not suitable for participants in the experiment * For different types of subjects, additional exclusion criteria: obese patients with normal glucose tolerance: fasting blood glucose ≥ 7.0 mmol/L or ≤ 3.9 mmol/L (excluding diabetes and hypoglycemia) * Obese patients before glucose: fasting blood glucose ≥ 7.0 mmol/L or ≤ 3.9 mmol/L (excluding diabetes and hypoglycemia) * Obese T2DM patients: Fasting blood glucose ≤ 3.9 mmol/L (excluding those with hypoglycemia)

Inclusion Criteria: * population includes all patients initiating a treatment with SGLT2i between April 1, 2020, and December 31, 2024. Exclusion Criteria: * None